Suman Jangid

Suman Jangid is a seasoned professional in global regulatory CMC with extensive experience in gene therapy and pharmaceutical regulations. Currently serving as the Director of Global Regulatory CMC for Gene Therapy at BridgeBio since April 2024, Suman has held prominent roles at Omega Therapeutics and Ultragenyx Pharmaceutical Inc., where responsibilities included managing IND, NDA, and clinical submissions, authoring critical CMC documents, and engaging with the FDA on regulatory correspondences. Suman's background includes a strong educational foundation in regulatory science and pharmaceutical sciences from the University of Southern California and Delhi Institute of Pharmaceutical Sciences and Research. A proven leader in the regulatory field, Suman has contributed to product life cycle management and driving regulatory strategies across various therapeutic areas.